DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Young-Jun | ko |
dc.contributor.author | Kim, Hak-Zoo | ko |
dc.contributor.author | Hwang, Seong-Ik | ko |
dc.contributor.author | Lee, Jeung-Eun | ko |
dc.contributor.author | Oh, Nu-Ri | ko |
dc.contributor.author | Jung, Kee-Hoon | ko |
dc.contributor.author | Kim, Min-Ah | ko |
dc.contributor.author | Kim, Kyung-Eun | ko |
dc.contributor.author | Kim, Ho-Min | ko |
dc.contributor.author | Lim, Nam-Kyu | ko |
dc.contributor.author | Jeon, Choon-Ju | ko |
dc.contributor.author | Lee, Gyun-Min | ko |
dc.contributor.author | Jeon, Byeong-Hwa | ko |
dc.contributor.author | Nam, Do-Hyun | ko |
dc.contributor.author | Sung, Hoon-Ki | ko |
dc.contributor.author | Nagy, Andras | ko |
dc.contributor.author | Yoo, Ook-Joon | ko |
dc.contributor.author | Koh, Gou-Young | ko |
dc.date.accessioned | 2013-03-12T01:07:56Z | - |
dc.date.available | 2013-03-12T01:07:56Z | - |
dc.date.created | 2012-02-06 | - |
dc.date.created | 2012-02-06 | - |
dc.date.issued | 2010-08 | - |
dc.identifier.citation | CANCER CELL, v.18, no.2, pp.171 - 184 | - |
dc.identifier.issn | 1535-6108 | - |
dc.identifier.uri | http://hdl.handle.net/10203/100911 | - |
dc.description.abstract | Two vascular growth factor families, VEGF and the angiopoietins, play critical and coordinate roles in tumor progression and metastasis. A single inhibitor targeting both VEGF and angiopoietins is not available. Here, we developed a chimeric decoy receptor, namely double anti-angiogenic protein (DAAP), which can simultaneously bind VEGF-A and angiopoietins, blocking their actions. Compared to VEGF-Trap or Tie2-Fc, which block either VEGF-A or angiopoietins alone, we believe DAAP is a highly effective molecule for regressing tumor angiogenesis and metastasis in implanted and spontaneous solid tumors; it can also effectively reduce ascites formation and vascular leakage in an ovarian carcinoma model. Thus, simultaneous blockade of VEGF-A and angiopoietins with DAAP is an effective therapeutic strategy for blocking tumor angiogenesis, metastasis, and vascular leakage. | - |
dc.language | English | - |
dc.publisher | CELL PRESS | - |
dc.subject | GROWTH-FACTOR-TRAP | - |
dc.subject | OVARIAN-CANCER | - |
dc.subject | SIGNAL-TRANSDUCTION | - |
dc.subject | VESSEL MATURATION | - |
dc.subject | INHIBITION | - |
dc.subject | ANTIBODY | - |
dc.subject | DOMAIN | - |
dc.subject | IMMUNOGLOBULIN | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | RESISTANCE | - |
dc.title | Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage | - |
dc.type | Article | - |
dc.identifier.wosid | 000281052000010 | - |
dc.identifier.scopusid | 2-s2.0-77955534812 | - |
dc.type.rims | ART | - |
dc.citation.volume | 18 | - |
dc.citation.issue | 2 | - |
dc.citation.beginningpage | 171 | - |
dc.citation.endingpage | 184 | - |
dc.citation.publicationname | CANCER CELL | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.contributor.localauthor | Kim, Ho-Min | - |
dc.contributor.localauthor | Lee, Gyun-Min | - |
dc.contributor.localauthor | Yoo, Ook-Joon | - |
dc.contributor.localauthor | Koh, Gou-Young | - |
dc.contributor.nonIdAuthor | Lim, Nam-Kyu | - |
dc.contributor.nonIdAuthor | Jeon, Choon-Ju | - |
dc.contributor.nonIdAuthor | Jeon, Byeong-Hwa | - |
dc.contributor.nonIdAuthor | Nam, Do-Hyun | - |
dc.contributor.nonIdAuthor | Sung, Hoon-Ki | - |
dc.contributor.nonIdAuthor | Nagy, Andras | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Cellcycle | - |
dc.subject.keywordPlus | GROWTH-FACTOR-TRAP | - |
dc.subject.keywordPlus | OVARIAN-CANCER | - |
dc.subject.keywordPlus | SIGNAL-TRANSDUCTION | - |
dc.subject.keywordPlus | VESSEL MATURATION | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordPlus | DOMAIN | - |
dc.subject.keywordPlus | IMMUNOGLOBULIN | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | RESISTANCE | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.